Royal Bank of Canada
FOLD

Royal Bank of Canada’s Amicus Therapeutics FOLD Stock Holding History

Royal Bank of Canada’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83K Sell
5,754
-19,638
-77% -$282K ﹤0.01% 5224
2025
Q4 		$361K Buy
25,392
+10,094
+66% +$99.2K ﹤0.01% 4403
2025
Q3 		$120K Sell
15,298
-106
-0.7% -$754 ﹤0.01% 5413
2025
Q2 		$88K Sell
15,404
-2,829
-16% -$18.3K ﹤0.01% 5678
2025
Q1 		$148K Sell
18,233
-130,579
-88% -$1.21M ﹤0.01% 4927
2024
Q4 		$1.4M Sell
148,812
-67,772
-31% -$704K ﹤0.01% 3285
2024
Q3 		$2.31M Sell
216,584
-71,453
-25% -$778K ﹤0.01% 2888
2024
Q2 		$2.86M Buy
288,037
+30,410
+12% +$312K ﹤0.01% 2631
2024
Q1 		$3.04M Sell
257,627
-82,445
-24% -$1.05M ﹤0.01% 2588
2023
Q4 		$4.83M Buy
340,072
+56,672
+20% +$643K ﹤0.01% 2265
2023
Q3 		$3.45M Buy
283,400
+31,226
+12% +$403K ﹤0.01% 2385
2023
Q2 		$3.17M Sell
252,174
-12,028
-5% -$143K ﹤0.01% 2449
2023
Q1 		$2.93M Sell
264,202
-21,133
-7% -$260K ﹤0.01% 2514
2022
Q4 		$3.48M Buy
285,335
+90,969
+47% +$1.02M ﹤0.01% 2415
2022
Q3 		$2.03M Buy
194,366
+5,584
+3% +$62.2K ﹤0.01% 2842
2022
Q2 		$2.03M Buy
188,782
+4,013
+2% +$33K ﹤0.01% 2886
2022
Q1 		$1.75M Sell
184,769
-19,337
-9% -$181K ﹤0.01% 3172
2021
Q4 		$2.36M Buy
204,106
+45,879
+29% +$511K ﹤0.01% 3008
2021
Q3 		$1.51M Buy
158,227
+11,657
+8% +$119K ﹤0.01% 3313
2021
Q2 		$1.41M Buy
146,570
+7,798
+6% +$76.1K ﹤0.01% 3360
2021
Q1 		$1.37M Buy
138,772
+111,017
+400% +$1.72M ﹤0.01% 3319
2020
Q4 		$642K Buy
27,755
+3,572
+15% +$73K ﹤0.01% 3916
2020
Q3 		$341K Buy
24,183
+11,595
+92% +$169K ﹤0.01% 4158
2020
Q2 		$190K Sell
12,588
-19,296
-61% -$235K ﹤0.01% 4485
2020
Q1 		$295K Sell
31,884
-96,310
-75% -$916K ﹤0.01% 4037
2019
Q4 		$1.25M Sell
128,194
-561
-0.4% -$5.13K ﹤0.01% 3267
2019
Q3 		$1.03M Buy
128,755
+4,936
+4% +$53.6K ﹤0.01% 3329
2019
Q2 		$1.54M Sell
123,819
-6,482
-5% -$82.3K ﹤0.01% 2956
2019
Q1 		$1.77M Sell
130,301
-383,265
-75% -$4.68M ﹤0.01% 2791
2018
Q4 		$4.92M Buy
513,566
+74,266
+17% +$816K ﹤0.01% 1996
2018
Q3 		$5.31M Buy
439,300
+111,035
+34% +$1.55M ﹤0.01% 2071
2018
Q2 		$5.13M Buy
328,265
+9,396
+3% +$142K ﹤0.01% 1986
2018
Q1 		$4.8M Sell
318,869
-152,140
-32% -$2.32M ﹤0.01% 2018
2017
Q4 		$6.78M Sell
471,009
-17,567
-4% -$241K ﹤0.01% 1851
2017
Q3 		$7.37M Sell
488,576
-438,220
-47% -$5.8M ﹤0.01% 1736
2017
Q2 		$9.33M Buy
926,796
+250
+0% +$2.01K ﹤0.01% 1543
2017
Q1 		$6.61M Buy
926,546
+915,150
+8,030% +$5.79M ﹤0.01% 1735
2016
Q4 		$57K Buy
11,396
+8,244
+262% +$57.1K ﹤0.01% 5184
2016
Q3 		$23K Buy
3,152
+3,052
+3,052% +$20.6K ﹤0.01% 5497
2016
Q2 		$1K Buy
+100
New +$699 ﹤0.01% 6240
2015
Q4 		– Sell
-3,422
Closed -$47K – 6699
2015
Q3 		$47K Sell
3,422
-45,778
-93% -$718K ﹤0.01% 5161
2015
Q2 		$696K Buy
49,200
+48,000
+4,000% +$577K ﹤0.01% 3260
2015
Q1 		$13K Buy
+1,200
New +$10.6K ﹤0.01% 5490
2013
Q4 		– Sell
-552
Closed -$1K – 5985
2013
Q3 		$1K Buy
+552
New +$1.39K ﹤0.01% 5954

Other funds holding FOLD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Royal Bank of Canada's FOLD Position: Q1 2026 in Review

Royal Bank of Canada reduced its Amicus Therapeutics (FOLD) stake by 77% in Q1 2026, selling an estimated $282K and leaving 5,754 shares worth $83K. The position accounts for ﹤0.01% of the portfolio, ranked #5224.

Royal Bank of Canada first reported a position in FOLD in Q3 2013 and has held it in 44 quarters since. The position peaked at $9.33M in Q2 2017. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Royal Bank of Canada held 5,754 shares of Amicus Therapeutics worth $83K as of Q1 2026.
  • Royal Bank of Canada sold 19,638 Amicus Therapeutics shares in Q1 2026, an estimated $282K.
  • Amicus Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5224 holding.
  • Royal Bank of Canada first reported a position in Amicus Therapeutics in Q3 2013 and has held it in 44 quarters since.
  • Royal Bank of Canada's Amicus Therapeutics position peaked at $9.33M in Q2 2017.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.